BioSpace News Archive

MouthWatch, LLC, a leader in innovative teledentistry solutions, digital case presentation tools and intraoral imaging devices, debuts significant upgrades to its provider-focused, all-in-one teledentistry platform at booth #4318 during the 2020 Chicago Midwinter Meeting.

Ultraviolet (UV) technology developed by the New York-based firm PurpleSun Inc. eliminates more than 96 percent of pathogens in operating rooms (ORs) and on medical equipment, compared to 38 percent using manual cleaning methods that rely on chemicals to disinfect surfaces, according to a study published this month in the American Journal of Infection Control (AJIC).

The Board of Directors of Invacare Corporation announced that it declared a cash dividend of $.0125 per share on its common shares payable April 17, 2020 to shareholders of record on April 3, 2020.

Baudax Bio, Inc. announced that the U.S. Food and Drug Administration has approved the New Drug Application for ANJESO™, which is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics..

Kala Pharmaceuticals, Inc., announced that the Company granted a non-statutory stock option to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced financial results for the quarter and full year ended Dec. 31, 2019.

Universal Display Corporation, enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, announced that its Board of Directors approved an increased first quarter cash dividend of $0.15 per share on the Company’s common stock, up from the previous quarter’s dividend of $0.10 per share.

Cerus Corporation announced complete financial results for the fourth quarter and year ended December 31, 2019.

PRINCETON, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. Agile Therapeutics intends to grant the underwriters a 30-day option to purchase an additional fifteen percent of the shares of common stock offered in the public offering. The proposed offering is

-- Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT Recipients; Enrollment Expected in Q2 2020 -- -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010 for the Treatment of IBS-C -- Conference Call Today at 4:30 p.m. (ET) --